BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension
International Journal of Molecular Sciences · 15.05.2024 · 25 (10) · 5403
DOI: 10.3390/ijms25105403 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.05.2024. Verfasst von Keytam S Awad und 8 weiteren Autor:innen. Beteiligte Einrichtung: Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Signal Transduction, Bone Morphogenetic Protein Receptors, Type II, PPAR gamma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute R24, Cardiovascular Medical Research and Education Fund (CMREF).
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a progressive cardiopulmonary disease characterized by pathologic vascular remodeling of small pulmonary arteries. Endothelial dysfunction in advanced PAH is associated with proliferation, apoptosis resistance, and endothelial to mesenchymal transition (EndoMT) due to aberrant signaling. DLL4, a cell membrane associated NOTCH ligand, plays a pivotal role maintaining vascular integrity. Inhibition of DLL4 has been associated with the development of pulmonary hypertension, but the mechanism is incompletely understood. Here we report that BMPR2 silencing in pulmonary artery endothelial cells (PAECs) activated AKT and suppressed the expression of DLL4. Consistent with these in vitro findings, increased AKT activation and reduced DLL4 expression was found in the small pulmonary arteries of patients with PAH. Increased NOTCH1 activation through exogenous DLL4 blocked AKT activation, decreased proliferation and reversed EndoMT. Exogenous and overexpression of DLL4 induced BMPR2 and PPRE promoter activity, and BMPR2 and PPARG mRNA in idiopathic PAH (IPAH) ECs. PPARγ, a nuclear receptor associated with EC homeostasis, suppressed by BMPR2 loss was induced and activated by DLL4/NOTCH1 signaling in both BMPR2-silenced and IPAH ECs, reversing aberrant phenotypic changes, in part through AKT inhibition. Directly blocking AKT or restoring DLL4/NOTCH1/PPARγ signaling may be beneficial in preventing or reversing the pathologic vascular remodeling of PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Critical Care Medicine Department, Clinical Center, NIH, Bethesda, MD 20892, USA.
- Critical Care Medicine and Pulmonary Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892, USA.
ORCID-Profile: Keytam S Awad, Jason M Elinoff, Robert L Danner
Förderung
- NHLBI NIH HHS
- National Heart Lung and Blood Institute R24
- Cardiovascular Medical Research and Education Fund (CMREF)
- National Institutes of Health Clinical Center
Zitieren
APA
Awad, K. S., Wang, S., Dougherty, E. J., Keshavarz, A., Demirkale, C. Y., Yu, Z. X., Miller, L., Elinoff, J. M., & Danner, R. L. (2024). BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 25(10), 5403. https://doi.org/10.3390/ijms25105403
Vancouver
Awad KS, Wang S, Dougherty EJ, Keshavarz A, Demirkale CY, Yu ZX, et al. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2024;25(10):5403. doi:10.3390/ijms25105403
BibTeX
@article{Awad2024,
author = {Awad, Keytam S and Wang, Shuibang and Dougherty, Edward J and Keshavarz, Ali and Demirkale, Cumhur Y and Yu, Zu Xi and Miller, Latonia and Elinoff, Jason M and Danner, Robert L},
title = {BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {10},
pages = {5403},
doi = {10.3390/ijms25105403}
}
EUVIMED